文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic
侵权投诉

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study

Kostas Triantaphyllopoulos, PhDLeigh Madden, MDInma Rioja, PhDDavid Essex, MDJacky Buckton, PhDRajneesh Malhotra, PhDKeith Ray, PhDMichael Binks, PhDEwa M. Paleolog, PhD

Please address correspondence and reprints requests to:

Dr Kostas Triantaphyllopoulos, Faculty of Medicine, Imperial College London

National Heart and Lung Institute, Guy Scadding Building,Dovehouse Street,

London SW3 6LY, United Kingdom.E-mail:

k.triantaphyllopoulos@imperial.ac.ukReceived on May 13, 2009; accepted in revised form on October 29, 2009.© Copyright EXPERIMENTALCLINICAL RHEUMATOLOGY AND

2010.Abbreviations:

A-SAA: ATP: acute phase serum amyloid A; CIA: adenosine triphosphate; CFA: collagen-induced arthritis; ELISA: complete Freund’s adjuvant; enzyme-linked immunosorbent BLC1/CXCL13: B lymphocyte assay;

FCS: chemoattractant; HUVEC: foetal calf serum hIL: cells; uman umbilical vein endothelial LPS: interleukin; MAPK: lipopolysaccharide;

MAPKAP 2: mitogen-activated protein mitogen-activated protein kinase; MCP: kinase-activated protein kinase 2; monocyte chemoattractant MKP: protein;

MSK: MAPK phosphatise;

mitogen- and stress-activated RA: kinase; STAT: rheumatoid arthritis;

signal transducers and activators TNF-VEGF: α: of transcription;

tumour necrosis factor α; vascular endothelial growth factorCon ict of interest: This work was sponsored by GlaxoSmithKline (GSK) through the Alternative Discovery

Initiative. Drs Rioja, Buckton and Binks are employees of GSK; Dr Malhotra is a former employee of GSB; Dr Ray is a former employee of GSB and declares a competing nancial interest; the other authors declare no competing interests.

Introduction

The host immune system is highly regu-lated in terms of space and time. Loss of this control can lead to a number of diseases, tis diseases, (RA), including chronic rheumatoid arthri-and systemic disorder, characterised by pro-septic neurodegenerative in ammatory shock. RA is a chronic disorders bowel and gressive destruction of articular cartilage and bone, and thought to be triggered by a combination of genetic susceptibility and exposure to environmental factors.The p38 mitogen-activated protein ki-nase (MAPK) pathway is involved in a number of cellular processes critical to the activation and in ltration of leukocytes, development of RA, for example, as well as production of in ammatory cytokines. kinase p38 is a serine/threonine kinase, Mitogen-activated protein and been characterised, namely p38four p38 MAPK isoforms p38α p38have β, no-acid γ, and p38δ, which share a 12-ami-TGY motif located at amino acid posi-activation loop containing a tions 180-182, which are subsequently phosphorylated at the residues Thr180 and Tyr182 leading to p38 MAPK ac-tivation. p38 MAPK occurs by tyrosine-speci c The inactivation process of MAPK tyrosine phosphatases 1 studied isoform is p38(MKP1) and (MKP) such as (1). threonine The most phosphatase was synthesis shown to be involved α MAPK, which extensively in (TNF-transcriptional α) and interleukin (IL)-1of tumour necrosis factor the bio-α More volved in the regulation of pro-in am-importantly, and translational β at the p38 MAPK is level. in-matory mediators to initiate leukocyte recruitment tokine gene expression (2).

and activation, and cy-Many p38 MAPK inhibitors have dem-onstrated ef cacy in animal models of arthritic inhibitors have been in phase II clini-disease and at least two p38 cal trials for RA; however many have failed due to unacceptable side-effects. In the the present study, we GW856553X MAPK inhibitory investigated compounds analogue GSK678361 for and its close structural cacy in mouse models of arthritis, and in vivo ef -in to in determine vitro validation whether studies, the compounds

in order 177

modulate genesis. The aims of this study were to in ammation and/or angio-investigate turally differences in these struc-ing similar compounds, by study-and the ef cacy and dose responses tions or side-effects in the animal set-most importantly adverse reac-ting. evaluated for the treatment of chronic GW856553X is currently being obstructive man phase II clinical trials. We deter-pulmonary disease in hu-mined the effect of single daily dosing with GW856553X in acute and chronic collagen-induced chronic model of arthritis we have used arthritis (CIA). The closely mimics RA and hence is a poten-tially good predictor of clinical ef cacy (3, 4). The inhibition by GW856553X of acute CIA was mirrored by disease amelioration was in chronic CIA, which tor, namely GSK678361. Furthermore, con rmed using another inhibi-when GSK678361 was administered to mice 2 weeks after onset of symptoms of able chronic CIA, joint to this compound was nism in ammation. abolish symptoms and reverse that GW856553X inhibited human en-of action studies Moreover, demonstrated mecha-dothelial cell angiogenesis reduced in vitro, and production pro-in ammatory These data suggest that p38 MAPK in-(IL-6, IL-8 and MCP-1). cytokine hibitors may have therapeutic potential for future use in RA.

Materials and methodsMaterials

GW856553X structurally MAPK, related and inhibitors GSK678361 of p38are αexhibit with a which also inhibit p38β but enzymes respect high degree of selectivity measuring and to receptors other protein (5). In kinases, assays and human GSK678361 the effects of GW856553 cells, the compounds were found to in-peripheral blood on LPS-stimulated mononuclear hibit tory cytokines TNF-production of the pro-in amma-31nM and 12nM respectively, data not α (IC50 values of shown). Similar potencies were found against IL-1Human recombinant vascular endothe-β, IL-6 and IL-8.

lial growth factor (VEGF) and human recombinant Systems, Abingdon, TNF-α were UK, and from human

R&D

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email